Sales +5% y-o-y, -6% vs. ABGSCe on lower delivery sales 11% adj.
Redeye provides a brief comment on Sprint Bioscience’s Q3 report.
Net sales SEK 183m, 10% vs ABGSCe, 13% vs Factset cons.
Decelerating growth in Q3 due to the weakened market Ework is prioritising profitability over growth...
Redeye comments on Sleep Cycle's Q3 2023 report, which was in line with our sales estimates but stro...
Net sales was above consensus (Refinitiv) in Q3. Clean operating profit margin was also better than ...
Redeye sees a Q3 report with solid ACV numbers, but with sales and EBIT hurt by lower Deliveries in ...
Sales +9% vs. ABGSCe, EBIT +75% vs. ABGSCe Organic growth of -10%, better than ABGSCe -20% Order boo...
Redeye retains its positive view on Lagercrantz following a Q2 report with strong margins.
Aktiekursen i Starbreeze har straffats rejält efter att spelaraktiviteten på PC-plattformen Steam ha...
Redeye gives a short comment on Ependion’s Q3 2023 report, which came in close to our forecasts, not...
Redeye comments on Stillfront's Q3-results which came in below our forecast, mainly owing to Albion ...
Redeye highlights its key assumptions ahead of the Q3 report, due 9 November.
Redeye updates our outlook after Q3. XVIVO delivers a improved gross and EBITDA margins and an overa...
51% beat on EBITDA in Q3 New strategy and mid-term financial targets Earnings revised up for '23e, b...
Q3e: 27% y-o-y ARR growth, adj. EBITDA of DKK -4.9m Decent Q3 despite seasonality headwinds; still n...
Norway and Denmark are steaming ahead... ...more than offsetting the weaker Sweden Profitability com...
Redeye lowers its estimates for the Q3 report which is due on Friday.
Sales +1% vs. ABGSCe, EBIT +50% on lower opex Outlook: expects the weak market to linger in the near...
Redeye briefly comments on Annexin Pharmaceuticals rights issue.
